4th Wet AMD and Diabetic Eye Disease Drug Development Wyndham Boston Beacon Hill, Boston

The 4ᵗʰ Wet AMD and Diabetic Eye Disease Drug Development Summit is returning to Boston this March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes.

Hear fresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics, Bayer, Boehringer Ingelheim, OcuTerra, Novartis, Genentech, and Adverum Biotechnologies and discover robust new content focusing on industry-specific topics such as new targets, in vivo and in vitro models, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization.